Botanix Pharmaceuticals Limited (AU:BOT) has released an update.
Botanix Pharmaceuticals Limited, a clinical dermatology company, has announced an upcoming webinar to discuss the commercial launch plans and market insights for its lead product Sofdra, which is anticipated to receive FDA approval by late June 2024. The webinar will feature Executive Chairman Vince Ippolito, CEO Dr. Howie McKibbon, and other key commercial team members, aiming to engage stakeholders as the company prepares to introduce Sofdra as a new treatment for hyperhidrosis. Botanix also has a pipeline of dermatology products in late-stage clinical development for various skin conditions.
For further insights into AU:BOT stock, check out TipRanks’ Stock Analysis page.
